Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.

Young Eun ChonDong Yun KimMi Na KimBeom Kyung KimSeung Up KimJun Yong ParkSang Hoon AhnYeonjung HaJoo Ho LeeKwan Sik LeeBeodeul KangJung Sun KimHong Jae ChonDo Young Kim

Published in: Clinical and molecular hepatology (2024)

In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.

Keyphrases

current status
locally advanced
combination therapy
replacement therapy
smoking cessation